Diabetics to benefit under latest FDA biosimilar guidance

The Food and Drug Administration (FDA) has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US Congress confirms new drug patent listing law

22 December 2020 A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.

article

FDA to alter biosimilar ‘suffix’ policy

8 March 2019 The US Food and Drug Administration yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

Biotechnology

FDA releases plan to boost biosimilars development

13 December 2018 The US Food and Drug Administration has announced new measures to advance the development of biosimilar medicines.